PWSA Blog

Soleno Therapeutics to Be Acquired by Neurocrine Biosciences: What This Means for the PWS Community

On Monday, April 6, 2026, PWSA | USA received a letter from our partners at Soleno Therapeutics sharing significant news: Soleno has agreed to be acquired by Neurocrine Biosciences.

Soleno describes this as an exciting development, noting that the transaction “marks an exciting milestone for our company and represents the next step in our efforts to bring VYKAT™ XR (diazoxide choline) extended-release tablets to more people impacted by hyperphagia with Prader-Willi syndrome.”

Neurocrine Biosciences is a leading biopharmaceutical company with a strong track record in developing medicines for patients with rare and under-addressed conditions, including four FDA-approved medicines currently on the market. Soleno has emphasized that Neurocrine is approaching this acquisition with a focus on accelerating growth, not cost-cutting, and brings significant scale, resources, and expertise to support that mission.

For families in the PWS community, Soleno shared that their commitment remains unchanged. They have confirmed they will continue working closely with PWSA | USA to advance awareness and advocacy for patients, families, and caregivers, and ensured patients will continue to receive the medicines they depend on. The two companies will continue to operate independently until the transaction closes, which is expected within 90 days, pending regulatory approvals. 

PWSA | USA will continue to monitor this transition closely and keep our community informed every step of the way.

Share this!

Scroll to top